Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2869 - MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study

Date

09 Oct 2016

Session

Poster display

Presenters

Anna Estival

Citation

Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367

Authors

A. Estival1, E. Pineda2, M. Martinez-Garcia3, J. Marruecos4, C. Mesía5, A. Lucas6, M. Macia6, M. Gil5, O. Gallego7, E. Verger8, S. Del Barco4, R. Fuentes4, J. Craven7, N. García1, S. Villà9, J.M. Velarde1, C. Carrato10, T. Ribalta11, O. Arpi12, C. Balana1

Author affiliations

  • 1 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 2 Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 3 Department Of Medical Oncology, University Hospital del Mar, Barcelona/ES
  • 4 Medical Oncology, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona/ES
  • 5 Medical Oncology, Institut Catala de Oncologia, L'Hospitalet de Llobregat, Barcelona/ES
  • 6 Radiation Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08908 - Barcelona/ES
  • 7 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 8 Radiotherapy, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 9 Radiation Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 08916 - Badalona/ES
  • 10 Pathology, Hospital universitari germans trias i pujol, 08916 - Badalona/ES
  • 11 Pathology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 12 Cancer Research Program Imim, University Hospital del Mar, Barcelona/ES
More

Resources

Abstract 2869

Background

LR/PsP is more frequent in Met patients than in UnMet ones and it is considered an expression of therapeutic efficacy due to the combination with temozolomide and radiotherapy (TMZ&RT) of the Stupp's scheme. Our aim was to figure out if an ER at first evaluation (no PsP) was better or worse than a LR/PsP.

Methods

From the GLIOCAT study data base (432p) we identified those patients who had the first disease assessment within 60 days after the last day of concurrent TMZ&RT having further evaluations at 3/6 months or until progression while continuing on adjuvant TMZ treatment (256p). We defined ER as those patients without progression at first evaluation, and LR/ PsP as those that progressed at first evaluation but improved or maintained stable disease at subsequent evaluations.

Results

At first evaluation 128/256 (50%) p had an ER and 128/256 (50%) were at suspected progression (P); 56 of them improved at second and 4 at third evaluation (so 60 patients (23.5%) were considered as LR/PsP and 68 p (26.5%) were real P. PsP/LR was seen for any kind of initial surgery (0.12) and was more frequently seen in Met p (66%) than in unMet ones (34%). Conversely Met p had less real progressions (37.7%) than unMet p (62.3%) p = 0.01. All IDH1 mutated p (9) had ER (7) or PsP/LR (2) to treatment. Median Overall Survival (OS) was not different for patients with LR/PsP (17.9m) than those with ER (19.7); P = 0.48. (OS was only 12.3m for P patients). Nevertheless, Met p lived longer if they had ER (N = 45: 30.9m) than if they had LR/PsP (N = 33: 17.9m); P = 0.59. This held not true for unMet p: ER (N = 53: 18.0m) vs LR/PsP (N = 17: 17.9m); P = 0.44.

Conclusions

Although differences were not significant, our results suggest that LR/PsP does not increase survival and that it is a deleterious effect especially for Met p where it is more frequently observed. This should be explored in a larger series.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Marató TV3

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings